Haleon/$HLN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Haleon
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Ticker
$HLN
Sector
Primary listing
NYSE
Employees
24,535
Headquarters
Website
Haleon Metrics
BasicAdvanced
$45bn
41.74
$0.25
0.25
$0.18
2.46%
Price and volume
Market cap
$45bn
Beta
0.25
52-week high
$11.28
52-week low
$8.65
Average daily volume
10m
Dividend rate
$0.18
Financial strength
Current ratio
0.922
Quick ratio
0.699
Long term debt to equity
47.361
Total debt to equity
52.621
Dividend payout ratio (TTM)
36.71%
Interest coverage (TTM)
7.21%
Profitability
EBITDA (TTM)
3,647.998
Gross margin (TTM)
64.77%
Net profit margin (TTM)
15.11%
Operating margin (TTM)
22.69%
Effective tax rate (TTM)
21.93%
Revenue per employee (TTM)
$598,460
Management effectiveness
Return on assets (TTM)
4.65%
Return on equity (TTM)
10.27%
Valuation
Price to earnings (TTM)
41.742
Price to revenue (TTM)
6.275
Price to book
2.07
Price to tangible book (TTM)
-3.69
Price to free cash flow (TTM)
31.161
Free cash flow yield (TTM)
3.21%
Free cash flow per share (TTM)
0.33
Dividend yield (TTM)
1.78%
Forward dividend yield
2.46%
Growth
Revenue change (TTM)
-1.81%
Earnings per share change (TTM)
17.83%
3-year revenue growth (CAGR)
0.53%
3-year earnings per share growth (CAGR)
17.25%
3-year dividend per share growth (CAGR)
43.55%
What the Analysts think about Haleon
Analyst ratings (Buy, Hold, Sell) for Haleon stock.
Haleon Financial Performance
Revenues and expenses
Haleon Earnings Performance
Company profitability
Haleon News
AllArticlesVideos
FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca
Invezz·5 days ago
Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaboration
Business Wire·4 weeks ago
Futura swaps Haleon for Market Performance Group to drive US Eroxon sales
Proactive Investors·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.